Barclays Lowers Illumina (NASDAQ:ILMN) Price Target to $77.00

Illumina (NASDAQ:ILMN) had its price objective dropped by equities researchers at Barclays from $100.00 to $77.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has an “underweight” rating on the life sciences company’s stock. Barclays‘s target price indicates a potential upside of 10.05% from the company’s current price.

A number of other equities analysts also recently commented on the stock. Stephens reissued an “overweight” rating and issued a $156.00 target price on shares of Illumina in a research note on Tuesday, March 11th. Royal Bank of Canada dropped their price objective on Illumina from $128.00 to $112.00 and set an “outperform” rating on the stock in a report on Tuesday. HSBC cut Illumina from a “buy” rating to a “hold” rating and set a $100.00 target price for the company. in a research note on Friday, February 28th. Hsbc Global Res downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 28th. Finally, TD Cowen downgraded shares of Illumina from a “buy” rating to a “hold” rating and dropped their target price for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $138.70.

Illumina Trading Down 8.3 %

Shares of NASDAQ:ILMN traded down $6.33 during trading on Thursday, reaching $69.97. The stock had a trading volume of 587,525 shares, compared to its average volume of 2,247,321. Illumina has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The business has a fifty day moving average price of $90.77 and a 200-day moving average price of $123.08. The stock has a market cap of $11.08 billion, a P/E ratio of -9.12, a PEG ratio of 1.60 and a beta of 1.38. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, analysts anticipate that Illumina will post 4.51 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Bank of Stockton lifted its position in shares of Illumina by 3.8% in the 4th quarter. Bank of Stockton now owns 2,162 shares of the life sciences company’s stock worth $289,000 after acquiring an additional 80 shares during the period. Stephens Inc. AR lifted its position in Illumina by 1.4% in the fourth quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company’s stock worth $885,000 after purchasing an additional 90 shares during the period. Spire Wealth Management boosted its stake in Illumina by 26.0% during the fourth quarter. Spire Wealth Management now owns 470 shares of the life sciences company’s stock worth $63,000 after buying an additional 97 shares in the last quarter. IFP Advisors Inc raised its stake in shares of Illumina by 19.1% in the 4th quarter. IFP Advisors Inc now owns 617 shares of the life sciences company’s stock valued at $82,000 after buying an additional 99 shares in the last quarter. Finally, Freedom Investment Management Inc. lifted its holdings in shares of Illumina by 3.7% during the 4th quarter. Freedom Investment Management Inc. now owns 2,856 shares of the life sciences company’s stock worth $382,000 after acquiring an additional 101 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.